Immunization with a streptococcal multipleepitope recombinant protein protects mice against invasive group A streptococcal infection

Chih Feng Kuo, Nina Tsao, I. Chen Hsieh, Yee Shin Lin, Jiunn Jong Wu, Yu Ting Hung

研究成果: Article

3 引文 (Scopus)

摘要

Streptococcus pyogenes (group A Streptococcus; GAS) causes clinical diseases, including pharyngitis, scarlet fever, impetigo, necrotizing fasciitis and streptococcal toxic shock syndrome. A number of group A streptococcus vaccine candidates have been developed, but only one 26-valent recombinant M protein vaccine has entered clinical trials. Differing from the design of a 26-valent recombinant M protein vaccine, we provide here a vaccination using the polyvalence epitope recombinant FSBM protein (rFSBM), which contains four different epitopes, including the fibronectin-binding repeats domain of streptococcal fibronectin binding protein Sfb1, the C-terminal immunogenic segment of streptolysin S, the C3-binding motif of streptococcal pyrogenic exotoxin B, and the C-terminal conserved segment of M protein. Vaccination with the rFSBM protein successfully prevented mortality and skin lesions caused by several emm strains of GAS infection. Anti-FSBM antibodies collected from the rFSBM-immunized mice were able to opsonize at least six emm strains and can neutralize the hemolytic activity of streptolysin S. Furthermore, the internalization of GAS into nonphagocytic cells is also reduced by anti-FSBM serum. These findings suggest that rFSBM can be applied as a vaccine candidate to prevent different emm strains of GAS infection.

原文English
文章編號0174464
期刊PloS one
12
發行號3
DOIs
出版狀態Published - 2017 三月

指紋

Immunization
Streptococcal Infections
Recombinant Proteins
recombinant proteins
immunization
Vaccines
vaccines
fibronectins
Streptococcus
mice
Fibronectins
infection
epitopes
Epitopes
Proteins
proteins
vaccination
Streptococcus pyogenes
exotoxins
septic shock

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

引用此文

Kuo, Chih Feng ; Tsao, Nina ; Hsieh, I. Chen ; Lin, Yee Shin ; Wu, Jiunn Jong ; Hung, Yu Ting. / Immunization with a streptococcal multipleepitope recombinant protein protects mice against invasive group A streptococcal infection. 於: PloS one. 2017 ; 卷 12, 編號 3.
@article{288c9c97df0a4af2895e93b92d61dc4f,
title = "Immunization with a streptococcal multipleepitope recombinant protein protects mice against invasive group A streptococcal infection",
abstract = "Streptococcus pyogenes (group A Streptococcus; GAS) causes clinical diseases, including pharyngitis, scarlet fever, impetigo, necrotizing fasciitis and streptococcal toxic shock syndrome. A number of group A streptococcus vaccine candidates have been developed, but only one 26-valent recombinant M protein vaccine has entered clinical trials. Differing from the design of a 26-valent recombinant M protein vaccine, we provide here a vaccination using the polyvalence epitope recombinant FSBM protein (rFSBM), which contains four different epitopes, including the fibronectin-binding repeats domain of streptococcal fibronectin binding protein Sfb1, the C-terminal immunogenic segment of streptolysin S, the C3-binding motif of streptococcal pyrogenic exotoxin B, and the C-terminal conserved segment of M protein. Vaccination with the rFSBM protein successfully prevented mortality and skin lesions caused by several emm strains of GAS infection. Anti-FSBM antibodies collected from the rFSBM-immunized mice were able to opsonize at least six emm strains and can neutralize the hemolytic activity of streptolysin S. Furthermore, the internalization of GAS into nonphagocytic cells is also reduced by anti-FSBM serum. These findings suggest that rFSBM can be applied as a vaccine candidate to prevent different emm strains of GAS infection.",
author = "Kuo, {Chih Feng} and Nina Tsao and Hsieh, {I. Chen} and Lin, {Yee Shin} and Wu, {Jiunn Jong} and Hung, {Yu Ting}",
year = "2017",
month = "3",
doi = "10.1371/journal.pone.0174464",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

Immunization with a streptococcal multipleepitope recombinant protein protects mice against invasive group A streptococcal infection. / Kuo, Chih Feng; Tsao, Nina; Hsieh, I. Chen; Lin, Yee Shin; Wu, Jiunn Jong; Hung, Yu Ting.

於: PloS one, 卷 12, 編號 3, 0174464, 03.2017.

研究成果: Article

TY - JOUR

T1 - Immunization with a streptococcal multipleepitope recombinant protein protects mice against invasive group A streptococcal infection

AU - Kuo, Chih Feng

AU - Tsao, Nina

AU - Hsieh, I. Chen

AU - Lin, Yee Shin

AU - Wu, Jiunn Jong

AU - Hung, Yu Ting

PY - 2017/3

Y1 - 2017/3

N2 - Streptococcus pyogenes (group A Streptococcus; GAS) causes clinical diseases, including pharyngitis, scarlet fever, impetigo, necrotizing fasciitis and streptococcal toxic shock syndrome. A number of group A streptococcus vaccine candidates have been developed, but only one 26-valent recombinant M protein vaccine has entered clinical trials. Differing from the design of a 26-valent recombinant M protein vaccine, we provide here a vaccination using the polyvalence epitope recombinant FSBM protein (rFSBM), which contains four different epitopes, including the fibronectin-binding repeats domain of streptococcal fibronectin binding protein Sfb1, the C-terminal immunogenic segment of streptolysin S, the C3-binding motif of streptococcal pyrogenic exotoxin B, and the C-terminal conserved segment of M protein. Vaccination with the rFSBM protein successfully prevented mortality and skin lesions caused by several emm strains of GAS infection. Anti-FSBM antibodies collected from the rFSBM-immunized mice were able to opsonize at least six emm strains and can neutralize the hemolytic activity of streptolysin S. Furthermore, the internalization of GAS into nonphagocytic cells is also reduced by anti-FSBM serum. These findings suggest that rFSBM can be applied as a vaccine candidate to prevent different emm strains of GAS infection.

AB - Streptococcus pyogenes (group A Streptococcus; GAS) causes clinical diseases, including pharyngitis, scarlet fever, impetigo, necrotizing fasciitis and streptococcal toxic shock syndrome. A number of group A streptococcus vaccine candidates have been developed, but only one 26-valent recombinant M protein vaccine has entered clinical trials. Differing from the design of a 26-valent recombinant M protein vaccine, we provide here a vaccination using the polyvalence epitope recombinant FSBM protein (rFSBM), which contains four different epitopes, including the fibronectin-binding repeats domain of streptococcal fibronectin binding protein Sfb1, the C-terminal immunogenic segment of streptolysin S, the C3-binding motif of streptococcal pyrogenic exotoxin B, and the C-terminal conserved segment of M protein. Vaccination with the rFSBM protein successfully prevented mortality and skin lesions caused by several emm strains of GAS infection. Anti-FSBM antibodies collected from the rFSBM-immunized mice were able to opsonize at least six emm strains and can neutralize the hemolytic activity of streptolysin S. Furthermore, the internalization of GAS into nonphagocytic cells is also reduced by anti-FSBM serum. These findings suggest that rFSBM can be applied as a vaccine candidate to prevent different emm strains of GAS infection.

UR - http://www.scopus.com/inward/record.url?scp=85016249229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016249229&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0174464

DO - 10.1371/journal.pone.0174464

M3 - Article

C2 - 28355251

AN - SCOPUS:85016249229

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - 0174464

ER -